Summary The effects of treatment with 5-FU/folinic acid on interleukin-2 related lymphocyte responses was investigated in 21 patients with advanced colorectal cancer. The treatment was not suppressive of IL-2 related lymphocyte responses. Furthermore, at certain time points in the treatment cycles the capacity to generate lymphokine-activated killer (LAK) cells from the peripheral blood mononuclear cells of these patients was significantly augmented above that observed prior to treatment. These results provide a logical basis for the design of regimens which combine two approaches, each of low individual therapeutic efficacy, to treat patients with advanced colorectal cancer in the hope of increasing clinical response rates.
Cancer therapy with the recombinant lymphokine interleukin-2 (IL-2) is based on the in vivo activation of lymphokineactivated killer (LAK) cells and/or tumour-infiltrating cytotoxic T-lymphocytes (TIL) which can directly lyse tumour cells, although they may also act via other as yet ill-defined mechanisms. IL-2 therapy is finding a limited role in the treatment of patients with advanced malignant melanoma and renal cell cancer for which no suitable alternative chemotherapy has been discovered (Rosenberg et al., 1989) . Unfortunately, for patients with colorectal cancer neither IL-2 therapy nor chemotherapy with 5-fluorouracil (5-FU) alone appear to have a significant impact on disease progression and survival in more than 10-15% of patients, although combinations of 5-FU with folinic acid appear to provide greater response rates than does 5-FU alone (reviewed by Arbuck, 1989) .
Because few alternative treatment combinations exist for the common metastatic malignancies, a number of workers have explored the potential of combining chemotherapy with immunotherapy in a variety of experimental models and clinical scenarios. (North, 1982 , Ades et al., 1987 Papa et al., 1988; Eggermont & Sugarbaker, 1988; Lindemann et al., 1989; Stoter et al., 1989) . In the case of advanced colorectal cancer a number of empirically-designed clinical protocols combining 5-FU with IL-2 are being pursued (Hamblin et al., 1989; C. Franks, personal communication) . It is often assumed that most clinically effective chemotherapy regimens have immunosuppressive effects (Kempf & Mitchell, 1984; Powell et al., 1990) . Thus their combination with such agents as IL-2 may at first sight be illogical because some types of immunosuppression diminish the efficacy of immunotherapy (Vetto et al., 1987; Papa et al., 1986) . To investigate this in the context of colorectal cancer, we have examined the effects of a chemotherapeutic regimen, considered to have some clinical efficacy in colorectal cancer (Erlichman et al., 1988) , on natural killer (NK) cell activity, LAK cell induction, T-cell proliferation and IL-2 production. Paradoxically, rather than being immunosuppressive in this context, the use of cycles of 5-FU/folinic acid appears to augment these responses. These findings may provide a logical basis for the design of clinical chemo-immunotherapeutic protocols in humans suffering from colorectal cancer.
Patients and methods
Patients and details of treatment These investigations were conducted in 21 consecutive patients referred to this unit for consideration for liver resection Correspondence: P.J. Guillou. Received 24 April 1990; and in revised form 30 July 1990.
for liver metastases (n = 14) or 'second-look' surgery for locally recurrent (n = 7) colorectal cancer but who were found, on detailed investigation, to be unsuitable for further resectional surgery. All had undergone previous resection of their primary lesion between 3 and 38 months prior to referral. There were eight females and 13 males with a mean age of 60.7 ± 9.4 ( ± s.d.) years (range 46 -79 years). All were symptomatic from their disease, had a WHO performance index of 0 or 1, and had requested further treatment. Treatment consisted of 5-FU plus folinic acid administered according to the regimen described by Doroshow et al. (1987) . Briefly, high-dose folinic acid (500 mg -2 day-') was given by continuous infusion for 6 days and 5-FU at a dose of 370 mg m-2 by intravenous push daily for 5 days commencing 24 h after the start of the folinic acid infusion. This was repeated at 28-day intervals for two cycles following which the patients were evaluated for disease stability, disease progression or radiological response at 56 days after initiating therapy. All 21 patients received two cycles of therapy but no further treatment was administered to patients with progressive disease whereas therapy was continued monthly for a further 4 months in those with stable disease (no change in size of measurable lesion) or in whom there was radiological evidence of a partial tumour response. Tumour response was defined as a reduction of greater than 50% or more in the product of two measurable diameters of a preselected, defined indicator lesion. According to this definition 12 patients had progressive disease and ceased therapy after 2 months. Of the remaining nine patients, four had static disease (three with liver metastases and one with local recurrence) which remained static for 3, 4, 5 and 6 months respectively. Five (Monson et al., 1987) using the K562 erythroleukaemic cell line as an NK-sensitive target cell, or, for the quantification of spontaneous lymphocytotoxicity against an NK-resistant target, the colorectal cancer cell line, COL0205. Lymphokine-activated killer (LAK) cells were also generated from these PBMC by a previously reported method (Guillou et al., 1989) . Briefly 107 PBMC were cultured in 10 ml volumes of RPMI medium containing 10% fetal calf serum in the presence of 1,000 units ml-' of recombinant interleukin-2 (IL-2) (kindly provided by EuroCetus Ltd) for a period of 4 days. The activated lymphocytes recovered at the end of this period were then utilised as effector cells in a 4 h 5'Cr-release assay against the NKresistant DAUDI and COLO205 cell lines. On occasions when there were insufficient cells available to perform LAK assays against both targets, the cytotoxicity assay against COLO205 was omitted. NK and LAK assays were conducted at effector:target ratios ranging from 50:1 to 6.25:1. The percentage specific 5'Cr released at each effector:target cell ratio was calculated according to the usual formula as follows: % Specific 51Cr released= experimental 5"Cr-release -spontaneous 5'Cr-release 1 maximum 5"Cr-incorporated -spontaneous 51Cr-release x 00 where spontaneous 5'Cr-release is that obtained from a 4h incubation of 103 target cells alone, and maximum 5'Crrelease is that which is released following treatment of 103 target cells with a detergent solution. In these studies the ratio of spontaneous to maximum 5"Cr-release never exceeded 15%. The specific 5'Cr-release data were then converted to lytic units defined as the number of cells per 107 lymphocytes required to cause 30% specific 5'Cr-release from the tumour target cell in question.
Unfractionated PBMC from these patients were also activated with concanavalin A (Con A) to quantify the effects of therapy on lymphocyte proliferation and IL-2 production. 105 cells per well in 0.2 ml RPMI/10% FCS were cultured in quadruplicate in 96-well flat-bottomed microtitre plates (Nunc, Gibco Ltd, UK) in the presence of I0Og ml-' of Con A (Sigma, UK). Quadruplicate control wells containing no Con A were also prepared. The microplates were incubated for 24 h in 5% CO2 in humidified air following which 100 ttl supernatant was carefully withdrawn from each Con A activated well, pooled and stored at -20°C for subsequent IL-2 assay. A similar volume was discarded from each of the unstimulated wells, and in all wells this was replaced by 100 fsl medium containing 0.1I Ci of 3H-thymidine. Culture was continued for a further 16 h. The cells were harvested onto glass fibre discs using an automatic cell harvester (Dynatech, UK). The IL-2 content of supernatants from lectin-activated lymphocytes was measured by the bioassay described by Gillis et al. (1987) using the IL-2 dependent cloned murine CTLL-2 cell line as an indicator cell. These were cultured in 96-well flat bottomed microtitre trays at a concentration of 4 x 103 cells per well in the presence of doubling dilutions of supernatants derived from the Con A-activated peripheral blood mononuclear cells. The cultures were incubated for 24 h at 37°C in a humidified atmosphere of 5% CO2 in air, pulsed with 0.1I Ci 3H-thymidine per well for 6 h, and then harvested for beta counting as described above. Each assay included doubling dilutions of a standard recombinant IL-2 preparation containing 100 Cetus units of IL-2 ml-' and the amount of IL-2 present in the supernatant in question was then calculated by probit analysis as previously described (Monson et al., 1986) .
Statistical analyses
For ease of presentation and analysis, data from the 5'Crrelease assays was converted into log,0 lytic units. Figure 2 , where again the data are expressed in log,0 lytic units but on a rather more contracted vertical scale than those data shown in Figure 1 .
It can be seen that at the end of the first cycle of therapy (day 28) there was a statistically significant increase in the capacity to generate LAK cells from the peripheral blood mononuclear cells of these patients (U = 109.5, P = 0.05) and which was already evident on day 14 after the initiation of therapy (U = 67, P = 0.015). Furthermore, on measuring LAK generation 2 days following the administration of the next cycle of therapy (i.e. on day 35 following initiation of therapy) there was a further rise in LAK generation which was again significantly greater than that seen prior to treatment (U = 8, P = 0.005) and also significantly higher than that seen at the end of the first month of therapy on day 28 (U = 19, P = 0.049). Thereafter, LAK cell generation progressively declined although on day 56 of the treatment it still remained significantly higher than that seen on day 0 (U = 50, P = 0.036). By the 12th week after initiation of treatment, LAK cell generation was not significantly different from that seen prior to treatment (U = 20, P = 0.14), although the numbers of patients available for study at this stage were smaller, 12 patients having been withdrawn from therapy. (U = 104.5, P = 0.024) and 56 (U = 34.5, P = 0.0 12), although by day 84 the apparently higher LAK cell generation seen in these patients at this point did not reach statistical significance (U = 16.5, P = 0.077).
The mean loglo LAK activity induced against DAUDI cells at 1 and 2 months of therapy in patients who either had responded or had stable disease (n = 9) was higher than that of lymphocytes obtained from those with progressive disease (n = 12), although this did not achieve statistical significance ( Lectin-induced lymphocyte proliferation The pattern of change in lectin (Con A)-induced lymphocyte proliferation during this therapy are shown in Figure 4 . No significant changes were observed until the 28th day after the initiation of treatment (i.e. just prior to the administration of the second cycle of 5-FU/folinic acid), when the mean stimulation index was significantly higher than that observed prior to therapy (U = 78, P = 0.042). The stimulation index then appeared to fall immediately following the second cycle of treatment although it did not descend below baseline values. Thereafter the mean stimulation index rose progressively and just prior to the third infusion cycle was again significantly higher than that seen prior to therapy (U = 18, P = 0.02) and also was significantly higher than that seen on day 35 (U = 25, P = 0.04). Data obtained subsequent to day 56 of treatment were too small for statistical analysis to be valid.
IL-2 production The production of IL-2 by Con-A-activated lymphocytes during 5-FU/folinic acid therapy is shown in Figure 5 . There IL-2 on relatively IL-2 resistant tumours in rodents (Papa et al., 1988; Rosenstein et al., 1986) . This combination may have some merit when applied clinically (Mitchell et al., 1988) . However, other protocols have been introduced on an empirical basis without prior study of the influence which the chemotherapeutic agent has on the desirable immunological events induced by IL-2 (Stoter et al., 1989; Flaherty, 1989) .
Before embarking on the design of a chemo-immunotherapeutic protocol which involved the combination of IL-2 with 5-FU in patients with colorectal cancer, we wished to determine the influence on IL-2-based responses of a 5-FU regimen with demonstrable therapeutic efficacy. Currently this is considered to be best achieved by combining 5-FU with folinic acid (Erlichman et al., 1988; Kerr, 1989) . We anticipated that lymphocyte responses to cytokine activation would be diminished following an infusion of folinic acid accompanied by intravenous bolus 5-FU for 5 days. However, this combination proved not to be immunosuppressive and was followed by an augmented capacity to generate LAK cells from the peripheral blood lymphocytes of patients within the first month of initiating treatment. After the first month of therapy, wide individual variations in the capacity to generate LAK cells from the lymphocytes of these patients were observed but the augmented responses were maintained through second and third cycles of treatment although the magnitude of the subsequent changes appeared less marked than those observed through the first cycle of treatment (Figure 2) .
In considering the mechanism of this augmented LAK For example, CD3 + T-cells which possess the 1/6 T-cell receptor have been found to exert non-restricted tumour cell lysis on exposure to IL-2 in vitro (Borst et al., 1987) Accepting the difficulties inherent in comparing cytotoxicity data from one laboratory to another, the magnitude of change in LAK precursor availability we have observed following 5-FU/folinic acid therapy is at least comparable to that reported during the immediate 1 to 2 days of rebound lymphocytosis following therapy with IL-2 alone. It has been suggested that the magnitude of this rebound lymphocytosis, though not the level of inducible cytotoxicity, correlates with clinical response (West et al., 1987; Boldt et al., 1988) . Others have suggested that a high level of IL-2-primed LAK precursors occurs during the post-IL-2 rebound and is responsible for the response if further IL-2 is administered (Schoof et al., 1988) . Whatever the mechanism of the changes we describe, the clinical implications of these data are that at the very worst this therapeutic combination does not impair the development of the cellular cytotoxic responses which underlie IL-2 therapy and may promote them. On the basis of the results obtained from this study, such a regimen should administer 5-FU/folinic acid first, followed by IL-2 14 days later when there is an enhanced capacity for circulating LAK cell precursors to generate a cytolytic response. These data therefore provide a logical basis upon which to combine these two different therapeutic approaches in the hope of increasing clinical response rates in the treatment of unresectable colorectal cancer.
